[go: up one dir, main page]

WO2012019299A9 - Composés inhibiteurs de l'hépatite c - Google Patents

Composés inhibiteurs de l'hépatite c Download PDF

Info

Publication number
WO2012019299A9
WO2012019299A9 PCT/CA2011/050484 CA2011050484W WO2012019299A9 WO 2012019299 A9 WO2012019299 A9 WO 2012019299A9 CA 2011050484 W CA2011050484 W CA 2011050484W WO 2012019299 A9 WO2012019299 A9 WO 2012019299A9
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
inhibitor compounds
formula
compounds
hcv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2011/050484
Other languages
English (en)
Other versions
WO2012019299A1 (fr
Inventor
Paul J. Edwards
Mélissa LEBLANC
Benoît MOREAU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of WO2012019299A1 publication Critical patent/WO2012019299A1/fr
Publication of WO2012019299A9 publication Critical patent/WO2012019299A9/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des composés de formule (I) (Formule (I)) dans laquelle R1, R2, R3, R4 et n sont tels que définis dans la description, qui sont utiles en tant qu'inhibiteurs de la protéase NS3 du VHC pour le traitement de l'infection par le virus de l'hépatite C.
PCT/CA2011/050484 2010-08-11 2011-08-10 Composés inhibiteurs de l'hépatite c Ceased WO2012019299A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37257510P 2010-08-11 2010-08-11
US61/372,575 2010-08-11

Publications (2)

Publication Number Publication Date
WO2012019299A1 WO2012019299A1 (fr) 2012-02-16
WO2012019299A9 true WO2012019299A9 (fr) 2012-10-26

Family

ID=45567240

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2011/050484 Ceased WO2012019299A1 (fr) 2010-08-11 2011-08-10 Composés inhibiteurs de l'hépatite c

Country Status (1)

Country Link
WO (1) WO2012019299A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
BR112015007879A2 (pt) 2012-10-19 2017-07-04 Bristol Myers Squibb Co inibidores do vírus da hepatite c
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014071007A1 (fr) * 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
WO2014070964A1 (fr) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
EP2914614B1 (fr) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
EA029088B1 (ru) 2013-03-15 2018-02-28 Джилид Сайэнс, Инк. Макроциклические и бициклические ингибиторы вируса гепатита c
CN109354600B (zh) * 2018-11-29 2021-08-10 浙江海洋大学 一种牛磺酸修饰的新型阿拉斯加鳕鱼多功能肽的制备方法
CN115087634A (zh) * 2019-12-23 2022-09-20 新索思股份有限公司 制备n6-((2-叠氮乙氧基)羰基)赖氨酸的方法
WO2024258897A1 (fr) * 2023-06-13 2024-12-19 Dem Biopharma, Inc. Alcoxypyridinyle et composés apparentés et leur utilisation en thérapie

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7741281B2 (en) * 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100196321A1 (en) * 2009-01-30 2010-08-05 Glaxosmithkline Llc Compounds

Also Published As

Publication number Publication date
WO2012019299A1 (fr) 2012-02-16

Similar Documents

Publication Publication Date Title
WO2012019299A9 (fr) Composés inhibiteurs de l'hépatite c
MX2009008872A (es) Compuestos macrociclicos como inhibidores de proteasa ns3 del virus de hepatitis c.
WO2013074386A3 (fr) Inhibiteurs de la protéase ns3 du vhc
WO2008057995A3 (fr) Inhibiteurs de protéase de vhc
MY159958A (en) 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
MX2012000959A (es) Inhibidores de los virus flaviviridae.
WO2008057208A3 (fr) Inhibiteurs de protéase ns3 du vhc
WO2008051514A3 (fr) Inhibiteurs de la protéase ns3 du hcv
WO2008051475A3 (fr) Inhibiteurs de la protéase ns3 du vhc
MX2011006631A (es) Inhibidores de proteasa ns3 del virus hcv.
WO2008051477A3 (fr) Inhibiteurs de la protéase hcv ns3
IL198741A0 (en) Hepatitis c virus inhibitor compounds, compositions containing the same and uses thereof
MX2009004556A (es) Inhibidores de la proteasa ns3 del hcv.
MX2009004888A (es) Inhibidores del virus de la hepatitis c.
MX2012008221A (es) Inhibidores de virus flaviviridae.
EA200970805A1 (ru) Ингибиторы серинпротеаз для лечения hcv инфекций
MX2012008211A (es) Inhibidores de virus flaviviridae.
MX2010008523A (es) Inhibidores macrociclicos de serina proteasa.
EA201270423A1 (ru) Ингибиторы протеазы hcv
MX337050B (es) Compuestos 4'-azido-nucleósidos como anti-vhc.
NO20091845L (no) Macrocykliske peptider som hepatitt C virus-inhibitorer
NO20091846L (no) Makrocykliske peptider som hepatitt C virus- inhibitorer
MX2013006475A (es) Inhibidores macrociclicos de virus flaviviridae.
MX2012002925A (es) Inhibidores de virus flaviviridae.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11815964

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct app. not ent. europ. phase

Ref document number: 11815964

Country of ref document: EP

Kind code of ref document: A1